Clovis Archives -

AZ and MSD’s Lynparza gets fast prostate cancer FDA review

https://pharmaphorum.com/news/az-and-msds-lynparza-gets-fast-prostate-cancer-fda-review/

Clovis takes PARP prostate cancer pole position with fast FDA review of Rubraca

https://pharmaphorum.com/news/clovis-takes-parp-prostate-cancer-pole-position-with-fast-fda-review-of-rubraca/

New price gets Clovis’ PARP inhibitor on the CDF

https://pharmaphorum.com/news/new-price-gets-clovis-parp-inhibitor-on-the-cdf/

ESMO 2019 roundup

https://pharmaphorum.com/views-analysis-oncology/esmo-2019-roundup/

Clovis signs radiopharmaceuticals R&D deal with German biotech 3B

https://pharmaphorum.com/news/clovis-signs-radiopharmaceuticals-rd-deal-with-german-biotech-3b/

Clovis’ Rubraca is latest PARP drug showing promise in pancreatic cancer

https://pharmaphorum.com/news/clovis-rubraca/

FDA says Clovis’ Rubraca could be prostate cancer breakthrough

https://pharmaphorum.com/news/fda-says-clovis-rubraca-could-be-prostate-cancer-breakthrough/

AZ’s Lynparza becomes first PARP drug approved in breast cancer

https://pharmaphorum.com/news/azs-lynparza-becomes-first-approved-parp-drug-breast-cancer/

Clovis PARP drug gets fast US review in new ovarian cancer use

https://pharmaphorum.com/news/clovis-rubruca-fast-review/

Search